Security key
98420X202
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X202
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 83,045
- Total 13F value
- $20,007
- Share change
- +83,045
- SEC-reported price per share
- $0.24
- Number of holders
- 2
- Value change
- +$20,007
- Number of buys
- 2
- Shares outstanding
- 96,529,340
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
2
Top holders
2
XFOR full security history
Ownership snapshot
Full 13F holder table
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Ownership snapshot
Top reported holders of XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
13D/G
Lead comparable stake: 4.8%
13D/G row: VANGUARD GROUP INC
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD GROUP INC leads the comparable SEC ownership view at 4.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership
Top 5
VANGUARD GROUP INC
4.8%
Bain Capital Life Sciences Invest...
18%
NEA Management Company, LLC
16%
BlackRock, Inc.
12%
ACORN CAPITAL ADVISORS, LLC
7.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
13D/G
Company · The Vanguard Group
|
4.8%
from 13D/G
|
$6,019,463
8,200,903 shares
|
— | 31 Dec 2024 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
18%
|
$12,409,419
16,915,784 shares
|
— | 31 Dec 2024 |
| NEA Management Company, LLC |
13F
Company
|
16%
|
$10,994,311
14,986,793 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
12%
|
$8,114,089
11,060,645 shares
|
— | 31 Dec 2024 |
| ACORN CAPITAL ADVISORS, LLC |
13F
Company
|
7.7%
|
$5,363,093
7,310,650 shares
|
— | 31 Dec 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
7.6%
|
$5,233,147
7,133,515 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
83,045
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
2
Q1 2025 holders
2
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|